Moxifloxacin is a fluoroquinolone with a broad spectrum of activity and good 31 penetration into many tissues, including bone. Penetration of moxifloxacin into 32 bone has not yet been studied using compartmental modeling techniques. 33 Therefore, we determined rate and extent of bone penetration of moxifloxacin 34 and evaluated its pharmacodynamic profile in bone via Monte Carlo simulation. 
solutions to moxifloxacin-free bone tissue. Concentrations of moxifloxacin were 145 determined using reversed-phase HPLC with gradient elution and fluorometric 146 detection (296/504 nm). For evaluation of the calibration standards a weighted 147 linear regression (1/y 2 ) was performed with theoretical concentrations of 148 calibration standards and measured peak height ratios (peak height moxifloxacin 149 / peak height internal standard). 150
No interferences were observed in serum and bone for moxifloxacin and 151 the internal standard, including specimens of the three patients who had received 152 a dose of levofloxacin in addition to moxifloxacin. The linearity of moxifloxacin 153 calibration curves was demonstrated from 0.0100 to 5.00 mg/L in serum, and 154 from 0.009 to 4.76 mg/L in bone homogenate. The inter-day precision and 155 accuracy of the spiked quality control standards of moxifloxacin in human serum 156 ranged from 1.8 to 5.9% and from 95.1 to 103.8%. The inter-day precision and 157 accuracy of the spiked quality control standards of moxifloxacin in bone 158 homogenate ranged from 3.7 to 9.2% and from 94.7 to 97.6%. 159
Pharmacokinetic modeling: Models with one or two disposition 160 compartments in addition to bone were tested. Models with or without separate 161 compartments for cortical and cancellous bone as well as for samples from 162 femoral head and femoral head were considered. Informative and non-163
informative priors for ka were tested. The predictive performance of our final 164 model was tested via visual predictive checks, the generalized information 165 criterion for MAP estimation (MAP objective function), plots of observed versus 166 predicted concentrations, and residual plots. 167
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For the visual predictive check, the serum and bone concentration profiles 168 were simulated for 10,000 subjects. From these data the median, the 169 nonparametric 90% prediction interval (5% to 95% percentile), and the 170 nonparametric 50% prediction interval (25% to 75% percentile) for the predicted 171 profiles were calculated. These prediction interval lines were compared with the 172 original observed data. If the model described the data adequately, 10% of the 173 observed data points should fall outside the 90% prediction interval and 50% of 174 the data should fall outside the interquartile range. The median predicted 175 concentrations and the prediction intervals were compared to the observed data 176
and it was tested, whether the median and the prediction intervals mirrored the 177 central tendency and the variability of the raw data for the respective model. 178
Structural model: Moxifloxacin concentrations were determined in serum, 179 cortical bone, and cancellous bone. Due to the relatively small number of 180 samples from the femoral neck and to prevent making the model more complex, 181 our model did not distinguish between samples from femoral neck and femoral 182 head. A two compartment disposition model for moxifloxacin in serum and in the 183 peripheral compartment plus one peripheral compartment for each bone matrix 184 was used (Figure 1) . The differential equations for the model are: 185 The disposition parameters of moxifloxacin as described above have been 230 determined in absence of a bone compartment. As we used MAP-Bayesian 231 estimation (see below), we had to keep the amount of moxifloxacin in the bone 232 compartments minimal so that the serum PK was not affected by the presence of 233 the bone compartments. This can be achieved by choosing a small volume for 234 the bone compartment or equivalently a small value for the rate constants k 24 Therefore, we used a reverse engineering method (7) to propose a PKPD target 263 for moxifloxacin in serum and bone based on studies in osteomyelitis patients. 264
The reverse engineering method uses the success rate from clinical 265 studies in osteomyelitis patients, the expected AUCs after the doses given in 266 these studies, and published MIC distributions from the relevant time period to 267 derive the most likely target. The target which best predicts the observed clinical 268 success rate is derived via Monte Carlo simulation (MCS) in an iterative process. 269
We used published data from four studies (21, 22, 24, 37) AUCs were derived based on published PK data for ciprofloxacin (2, 54) or based 273 on the AUCs reported by the authors (37). A log-normal distribution was 274 assumed for clearance and a 25% protein binding was used for ciprofloxacin to 275 simulate the expected fAUCs for 5,000 virtual subjects for each osteomyelitis 276 study. We combined these fAUCs with susceptibility data for S. aureus (4, 8-10, 277 18, 20, 23, 31, 32, 42, 43, 49, 53) 47% and 55% (3, 40, 45, 54) . Therefore, an average protein binding of 50% was 292 assumed for moxifloxacin in serum. Between subject variability (BSV) was not 293 included for protein binding as the BSV for protein binding is already included in 294 the estimated variability for total clearance and for volume of distribution. For 295 moxifloxacin in bone, it was first assumed that it has the same binding as 296 ciprofloxacin. Other extents of binding (free fraction of 75%, 50%, 25%, or 10% of 297 the free fraction of ciprofloxacin in bone) were also assessed. 298
We simulated the serum and bone concentration time curves for 10,000 299 patients after an oral moxifloxacin dose of 400 mg q24h at steady-state in 300 absence of residual error. For mean equilibration half-lives between 4 and 30 min, the mean bone to serum 318 AUC ratios differed by less than 9% under all studied conditions. 319
Final parameter estimates from the MAP-Bayesian estimation in Adapt, 320 from WinBUGS and S-Adapt (results not shown) were similar, as shown in Table  321 1. Figure 3 shows the extent of moxifloxacin penetration into cortical and 322 cancellous bone, and its between subject variability, calculated from the ratios of 323 AUC cortical / AUC serum and AUC cancellous / AUC serum of 10,000 subjects that we 324 simulated at steady-state. 
The visual predictive checks showed acceptable predictive performance of 327 the final model for all three matrices (Figure 4) . The central tendency of the 328 concentrations in bone was slightly under-predicted between 2.5 and 3.5 h, 329
whereas it was predicted adequately in serum. The variability was well predicted 330 for all three matrices. This supported the use of our model in the MCS. 331
Concentration time profiles in serum and bone predicted by the final estimates 332 from WinBUGS (Table 1) were comparable to the predicted profiles shown in 333 were very similar, we used the average from these two studies investigating 344 clinical or microbiological outcome, i.e. fAUC SERUM /MIC ≥ 40 and AUC BONE /MIC ≥ 345 33 for MCS. In one of these two studies PK parameters were reported for several 346 subjects and could be used for calculation of the AUCs. The resulting targets 347 from these two studies (fAUC SERUM /MIC ≥ 40 and AUC BONE /MIC ≥ 33) fall 348 between the targets calculated from the other two studies (Table 2) Table 2 is usually not feasible to obtain concentrations at more than one time point and 407 even in case this was done, the blood circulation to the bone would be impaired 408 and this could bias the observed time course. While these limitations apply to the 409 vast majority of published bone penetration studies, we applied latest modeling 410 approaches to derive as much information as possible from the available data. 411
As most bone penetration studies (26), our study was performed in 412 patients with non-infected bone. In osteomyelitis patients, rate and extent of bone 413 penetration might differ. Blood flow into bone might be increased due to reactive 414 hyperemia or decreased due to pus, ischemic regions, and sequester. Some 415 studies (26) show higher concentrations in infected compared to non-infected 416 bone. The PK in bone might also be influenced by a potentially decreased bone 417 density in elderly patients. 418
Our study in hip replacement patients was a single dose trial. This reflects 419 the common practice for surgical prophylaxis where usually a single dose is given 420 before surgery, which might be followed by additional doses afterwards. As 421 moxifloxacin displays linear PK after single and multiple doses (48) We studied the concentrations of moxifloxacin in bone and serum between 445 2 and 7 h post the oral dose of moxifloxacin. The average concentration ratio 446 between serum and bone showed no obvious change with time during our 447 observation period. The observed data and initial modeling showed that the bone 448 penetration in our study was faster than expected, and equilibrium between 449 serum and bone was virtually achieved 2 h after dosing. Therefore, the bone and 450 the central compartment were in pseudo-equilibrium during our observation 451 
